Adherence, Compliance, and Persistency Publication

A small biopharma company wanted to leverage in-house claims data to generate RWE on compliance / persistency for its renal cell carcinoma (RCC) product compared to other vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) competitors.

We began by creating a patient-level database based on relevant claims and codes of interest. We also aligned with the client on key competitors to investigate.

For the analysis, we established the patient cohort through stability rules, overlapping treatment, and changes in line. We also aligned patient compliance / persistency definitions and observation time periods, then mapped the patient-level history of medication prescription and therapy duration.

We then wrote a final report and pressure-tested it for bias. Finally, our team aligned on a target forum and developed a poster presentation for it, as well as a manuscript for journal publication.

While the overall goal of the project was to generate RWE on compliance and persistence, the client was able to improve its line of therapy business rules and boosted its understanding of compliance and persistence by line, time period, and other data cuts. This generated significantly better insights into the product’s performance. The data were additive to a real-world effectiveness study that demonstrated superior patient tolerability through longer medication persistence when compared to key competitors.